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Edited by Robert BaroukiAbstract We demonstrated that ginsenoside-Re (Re), a phar-
macological active component of ginseng, is a functional ligand
of glucocorticoid receptor (GR) using competitive ligand-binding
assay (IC50 = 156.6 nM; Kd = 49.7 nM) and reporter gene as-
say. Treatment with Re (1 lM) raises intracellular Ca2+
([Ca2+]i) and nitric oxide (NO) levels in human umbilical vein
endothelial cells as measured using fura-2 and 4-amino-5-meth-
ylamino-2 0,7 0-diﬂuoroﬂuorescein diacetate, respectively. Wes-
tern blot analysis shows that Re increased phosphorylation of
endothelial nitric oxide synthase. These eﬀects were abolished
by GR antagonist RU486, siRNA targeting GR, non-selective
cation channel blocker 2-aminoethyldiphenylborate, or in the ab-
sence of extracellular Ca2+, indicating Re is indeed an agonistic
ligand for the GR and the activated GR induces rapid Ca2+ in-
ﬂux and NO production in endothelial cells.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Panax ginseng C.A. Meyer has been used as health tonics for
centuries in Chinese medication [1]. The pharmacologically
active components of ginseng are ginsenosides, which are
broadly categorized into 20(S)-protopanaxatriol (PPT) and
20(S)-protopanaxadiol (PPD), based on the number and the
position of the sugar moieties attached on the steroidal back-
bone. To date, more than 30 ginsenosides have been identiﬁed,
in which ginsenoside Re, a PPT, makes up 0.1% (w/w) and
0.7% (w/w) of ginseng root and berry extracts, respectively
[2]. Although, Re is a relative abundant ginsenoside, to date,
its bioavailability in mammalian species has not been docu-
mented. Re was previously suggested to be a highly stableAbbreviations: 2-APB, 2-aminoethyldiphenylborate; DAF-FM, 4-
amino-5-methylamino-20,7 0-diﬂuoroﬂuorescein; Dex, dexamethasone;
eNOS, endothelial nitric oxide synthase; GR, glucocorticoid receptor;
GRE, glucocorticoid responsive element; HUVEC, human umbilical
vein endothelial cell; [Ca2+]i, intracellular calcium ion concentration;
NO, nitric oxide
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doi:10.1016/j.febslet.2007.04.055pro-angiogenic compound by upregulating in vitro prolifera-
tion, migration, chemoinvasion and tube formation of human
umbilical vein endothelial cell (HUVEC), as well as ex vivo
aortic sprouting and in vivo neovascularization [3,4]. Angio-
genesis is the growth of new blood vessels from pre-existing
vasculatures. It is a highly regulated process controlled by
strict balance between the angiogenic promoters and inhibitors
[5]. It is an important physiological process required for
embryonic development, menstrual cycle and wound healing.
Calcium is one of the major angiogenesis regulators and key
mediator for endothelial cell proliferation [6,7], which is
adopted by many reputed angiogenic factors including vascu-
lar endothelial growth factor (VEGF) [7–9]. Here, we demon-
strated that Re stimulated the inﬂux of calcium ion in
HUVEC, at least partly, contributing to the angiogenic eﬀects
of Re.
We had previously reported that another angiogenic PPT,
ginsenoside-Rg1, induces rapid nitric oxide (NO) production
and other angiogenic actions through activation of glucocorti-
coid receptor (GR) [10,11]. Since, Re shares a high structural
correlation with Rg1 with only an additional rhamnose at C-
6 position (Fig. 1), we speculate that Re may also be a func-
tional ligand of the GR. To elucidate whether Re has direct
interaction with the GR, competitive ligand-binding assay
and transfection reporter gene assay were employed. Our data
established that Re binds to GR and induces a transient in-
crease in intracellular calcium ion concentration ([Ca2+]i), via
non-selective cation channel for phosphorylation and activa-
tion of endothelial nitric oxide synthase (eNOS) with an in-
crease in NO production. Thus the angiogenic property of
Re and its related ginsenosides can be exploited in angiother-
apy.2. Materials and methods
2.1. Experimental reagents
Ginsenoside-Re (Re) is a reference compound (purity >98%) pur-
chased form the Division of Chinese Materia Medica and Natural
Products, National Institute for the Control of Pharmaceutical and
Biological Products (NICPBP), Ministry of Public Health, China.
Stock solution of Re (50 mM) was prepared in sterile DMSO.
Culture medium M199, endothelial cell growth supplement (ECGS),
GR antagonist RU486, 2-aminoethyldiphenylborate (2-APB) were
purchased from Sigma (St. Louis, MO). eNOS inhibitor L-NMMA
was purchased from Cayman Chemical (Ann Arbor, MI). Foetal bo-
vine serum (FBS) was purchased from Gibco (Carlsbad, CA). Fura-
2-acetoxymethyl ester (AM), Pluronic F127 and NO sensitive ﬂuores-
cent dye 4-amino-5-methylamino-2 0,7 0-diﬂuoroﬂuorescein (DAF-FM)
diacetate were obtained from Molecular Probes (Leiden, Netherlands).ation of European Biochemical Societies.
Fig. 1. Illustrations depicted the molecular structures of ginsenosides Re and Rg1.
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HUVEC was obtained from Clonetics (San Diego, CA) and cultured
in complete medium 199 supplemented with 20% FBS, 20 lg/ml
ECGS, 90 U/ml heparin and 1% penicillin–streptomycin–neomycin
(PSN) in a humidiﬁed incubator at 37 C with 5% CO2. HUVEC
between passages 2–8 were used in these studies to ensure the genetic
stability of the culture.
For inhibitory assays, cells were pretreated, respectively with diﬀer-
ent antagonists or inhibitors, such as RU486 (10 lM), 2-APB (10 lM)
and L-NMMA (10 lM) for 30 min in assay medium 199 containing
only 90 U/ml heparin and 1% PSN. Cells transfected with the Smart-
Pool siRNA for silencing GR (M-003424-02) (Dharmacon, Lafayette,
CO) were incubated for 24 h prior to imaging. Knockdown eﬃcacy of
GR was previously demonstrated [10].
2.3. Measurement of intracellular Ca2+ concentration ([Ca2+]i)
[Ca2+]i was determined using the ﬂuorescent Ca
2+ indicator fura-2
AM. The circular coverslip containing the endothelial cells were pin-
ned in a specially designed chamber. The chamber was placed on the
stage of the Motic AE31 inverted microscope ﬁtted with a ·20 objec-
tive. It was then illuminated with a computer-controlled shutter lamb-
da 10-B ﬁlter wheel with mercury xenon light source (Intracellular
Imaging Inc., University of Cincinnati, Cincinnati, OH, USA).
Fura-2 loaded cells were excited with an alternating UV light at
340 and 380 nm. Images of the respective 510-nm emissions were col-
lected in 2-s intervals using InCytIm2 ratio ion measurement pro-
gramme version 5.27A (Intracellular Imaging Inc.). The emitted
light was transmitted to the collecting device and then to a MICRO-
PIXVGA camera. A calibration curve was constructed using a
standard calibration kit (Molecular Probes). For calcium-free experi-
ment, the assay medium was replaced by OCa2+-PSS (140 mM NaCl,
5 mM KCl, 1 mM MgCl2, 10 mM glucose, 2 mM EGTA, 5 mM
HEPES, pH 7.4) during imaging. Three individual samples were anal-
ysis in each trial and each data point is the mean of three independent
trials.
2.4. Measurement of NO
NO production was monitored using ﬂuorescent NO indicator
DAF–FM diacetate. HUVEC was loaded with 1 lM DAF–FM for
30 min in assay medium. Detection was made by measuring ﬂuores-
cence intensity excited at 495 nm and emitted at 515 nm with the same
setup as mentioned in ‘‘Measurement of intracellular Ca2+ concentra-
tion ([Ca2+]i)’’.2.5. Western blot analysis
Equal amount of proteins were separated by SDS–PAGE and trans-
ferred onto nitrocellulose membrane. The membrane was then incu-
bated with antibody against phospho-eNOS (Ser1177) (Upstate
Biotechnology Inc., Lake Placid, NY) for 3 h, followed by horseradish
peroxidase-conjugated secondary antibodies and the banding were
visualized by an ECL detection system. Then, the membranes were
stripped and re-probed with antibody against and eNOS (Upstate Bio-
technology Inc.). The bands were quantiﬁed by densitometric analysis
using Metamorph software.2.6. GR competitive ligand-binding assays
Commercially available GR competitive binding assay (Invitrogen)
was used according to the manufacturer’s instructions as previously
described [10]. Brieﬂy, serial 2-fold dilution of GR agonist dexa-
methasone (Dex) (0.9 nM to 1 lM) and Re (1.8 nM to 2 lM) were
competed with a proprietary ﬂuorescent glucocorticoid ligand
(Fluormone) provided in the kit, for binding to the human GR.
Fluorescence polarization was measured with a PTI Fluorescence
Lifetime Scanning Spectrometer, and the 50% inhibitory concentra-
tion (IC50) and the equilibrium dissociation constant (Kd) were deter-
mined.2.7. Reporter gene assay
pGRE-TA-SEAP reporter plasmids (BD Biosciences, Palo Alto,
CA) (0.5 lg/well of 24-well plate) or pTAL-SEAP (negative control)
was transiently transfected into HUVEC using Lipofectamine (Invitro-
gen). pGRE-TA-SEAP contains tandem repeats of glucocorticoid
responsive element (GRE) link to a downstream SEAP reporter gene.
pTAL-SEAP is an identical plasmid but without the GREs. After
transfection for 24 h, treatments were added and conditioned medium
were harvested after another 24 h. SEAP activity was assayed accord-
ing to the manufacturer’s protocol using the SEAP ﬂuorescence detec-
tion kit (BD Biosciences, San Jose, CA).2.8. Statistical analysis
Numerical results were analyzed using one-way ANOVA with Dun-
can post hoc test. For [Ca2+]i and NO measurement, nonparametric
analysis with Prism Software was employed. Values shown are means
of at least N = 3 experiments with ±S.D. Diﬀerences were considered
statistically signiﬁcant at a value of P 6 0.05.
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Fig. 2. Re induces elevation of [Ca2+]i in HUVEC. (A) Calcium
indicator fura-2 loaded HUVEC was treated with Re at 250, 500, 750
and 1000 nM. The [Ca2+]i was monitored in 2-s intervals using
InCytIm2 ratio ion measurement programme for 5 min. (B) Histogram
showing the fold change in [Ca2+]i over control. Cells treated with Re
(1 lM), or pretreatment with non-selective cation channel blocker 2-
APB (10 lM), or the use of Ca2+-free extracellular buﬀer, followed by
treatment with Re (1 lM). Area under the curve representing total free
calcium ion in 5 min was taken for analysis (N = 3; ±S.D.). *Means
data signiﬁcantly diﬀerent from control at a value of P 6 0.05.
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Fig. 3. Re induces phosphorylation of eNOS and NO production. (A)
Proteins (35 lg/lane) were separated on 10% SDS–PAGE and trans-
ferred onto nitrocellulose membrane. Protein loading was normalized
with reference to total eNOS. Phosphorylated eNOS (Ser1177) was
increased after Re (1 lM) treatment for 5 min. Total eNOS had no
change in quantity in all treatment groups. (B) NO production as
monitored in DAF-FM diacetate-ﬂuorescent dye loaded HUVEC. Re
increased NO production dose-dependently (250, 500, 750 and
1000 nM) in a time window of 10 min. (C) Histogram showing the
fold changes in NO production over control. Cells treated with Re
(1 lM), or pretreatment with non-selective cation channel blocker 2-
APB (10 lM), the use of Ca2+-free extracellular buﬀer, or NOS
inhibitor L-NMMA (10 lM), followed by treatment with Re (1 lM).
Area under the curve representing total NO production in 10 min was
taken for analysis (N = 3; ±S.D.). *Means data signiﬁcantly diﬀerent
from control at a value of P 6 0.05.
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3.1. Re stimulates [Ca2+]i via non-selective cation channels
[Ca2+]i in HUVEC was monitored using ﬂuorescence fura-2
AM dye. Re increased [Ca2+]i in a concentration-dependent
manner with 50% eﬀective concentration (EC50) at 316 nM
and [Ca2+]i was peaked at 30 s after treatment (Fig. 2A). We
also examined whether the Re-mediated [Ca2+]i elevation is a
result of calcium inﬂux from extracellular source or release
of Ca2+ from internal reservoir. As shown in Fig. 2B, pretreat-
ment with non-selective cation channel blocker 2-APB or
depletion of extracellular source of Ca2+ suppressed the respec-
tive increase of [Ca2+]i, indicating the source of Ca
2+ is exter-
nal.
3.2. Re induces NO production
Endothelial NOS is one of the direct targets of calcium sig-
naling. As revealed by Western blot analysis, Re (1 lM) acti-
vated eNOS via the increase of eNOS phosphorylation
(Ser1177) (Fig. 3A). Also, Re-enhanced production of NO as
determined using DAF-FM diacetate ﬂuorescence dye was in
a dose-dependent manner (Fig. 3B). Fluorescence gradually
accumulated in cells and reached plateau after peaking at
100 s (Fig. 3B). The EC50 for Re to induce NO production
was 615 nM. Re-induced activation of eNOS and NO produc-
tion were abrogated by pretreatment with 2-APB, absence of
extracellular Ca2+ or eNOS inhibitor L-NMMA (Fig. 3Aand C). These results provided evidence that Re-activated
eNOS is downstream of Ca2+ elevation.
3.3. Re binds to the GR
Owing to the structural similarity between Re and Rg1
(Fig. 1), Re was speculated to eﬀect via the GR like Rg1. A
competitive ligand-binding assay was performed to study the
speciﬁc binding of Re to the GR using a proprietary ﬂuores-
cent glucocorticoid ligand (Fluormone)-recombinant human
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Fig. 4. Competitive binding of Re to the GR and reporter gene assay.
(A) The competitive binding was determined by a ﬂuorescent polar-
ization-based assay using recombinant human GR and a proprietary
ligand (Fluormone). Dex served as a positive control. Fluorescent
polarization was expressed in millipolarization (mP). Data represent
the mean from three independent experiments. (B) HUVEC was
transiently transfected with a reporter gene containing GRE. Dex
(50 nM) and RU486 (10 lM) were used as positive and negative
controls (N = 3; ±S.D.). *Means data signiﬁcantly diﬀerent from
control at a value of P 6 0.05.
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Fig. 5. Eﬀects of Re are GR dependent. Cells treated with Re (1 lM),
or pretreatment with GR antagonist RU486 (10 lM), or transfected
with siRNA targeting GR or non-speciﬁc (NS)-siRNA, followed by
treatment with Re (1 lM). (A) Histogram showing the fold change in
[Ca2+]i over control. Area under the curve representing total free
calcium ion in 5 min was taken for analysis. (N = 3; ±S.D.). (B)
Western blot analysis probing with antibody against phosphorylated
eNOS. Protein loading was normalized with reference to total eNOS.
(C) Histogram showing the fold changes in NO production over
control. Area under the curve representing total NO production in 10
min was taken for analysis (N = 3; ±S.D.). *Means data signiﬁcantly
diﬀerent from control at a value of P 6 0.05.
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by Re results in a shift in the ﬂuorescent polarization of which
the relative binding aﬃnity of Re for the GR can be deter-
mined. The competitive ligand-binding assay indicated that
Re is indeed a ligand of the GR. The Kd values for Dex and
Re were 3.4 nM (IC50, 10.6 nM; R
2 = 0.99) and 49.7 nM
(IC50, 156.6 nM; R
2 = 0.98), respectively (Fig. 4A).
In the classical pathway of nuclear hormone receptor, the
receptor-ligand complex undergoes conformation changes
and translocates into the nucleus where it interacts with
GRE located on the promoter regions of target genes [12]. In
transfection reporter gene assay, Re was able to activate SEAP
transcription of a promoter containing three copies of the
GRE in HUVEC. Re (250 nM) showed a 2.4-fold SEAP
induction over untreated control and this eﬃcacy was compa-
rable with that of Dex (Fig. 4B). Both Re and Dex had no
eﬀect on pTAL-SEAP, a vector identical to pERE-TA-SEAP
but without the GRE (data not shown). RU486, a speciﬁc
GR antagonist, was used as a negative control that showedno transactivation of the reporter gene (Fig. 4B). Taken to-
gether, these results demonstrate that Re is indeed a functional
agonist for GR.
3.4. Eﬀects of Re are GR-dependent
Next, we examine whether Re eﬀects via GR. In the presence
of speciﬁc GR antagonist RU486 (10 lM) or using siRNA to
knockdown GR, Re-induced elevation of [Ca2+]i, eNOS phos-
phorylation and NO production were signiﬁcantly reduced
(Fig. 5A–C), while pretreatment with speciﬁc estrogen receptor
(ER) antagonist ICI 182780 (data not shown), or transfection
with non-speciﬁc siRNA had no inhibitory eﬀects, suggesting
the involvement of GR, but not ER, in the rapid responses ini-
tiated by Re.
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Panax ginseng has been used extensively in countries, includ-
ing the United States and many parts of Europe. The pharma-
cologically active ginsenosides were demonstrated to exert
beneﬁcial eﬀects to the cardiovascular system, in which ginse-
noside-Re was reported to stimulate vasodilation and angio-
genesis in vivo [3,13]. Angiogenesis is a fundamental process
in both physiological and pathological conditions. Therapeuti-
cal angiogenesis is now drawing more attention as a treatment
of chronic wound or gastric ulcer [14,15].
In this study, we demonstrated that Re stimulated Ca2+ in-
ﬂux via non-selective cation channel, the onset of calcium in-
ﬂux was rapid following by a quick decline (Fig. 2). The
necessity in limiting the duration of [Ca2+]i elevation may
due to the fact that prolonged elevation of calcium can be toxic
and may trigger apoptosis [16,17]. Calcium signaling regulates
a diversity of cellular responses, including cell cycle progres-
sion and NO production [18]. Yet, basal [Ca2+]i in the endothe-
lial cells is insuﬃcient in regulating the minimal activity of
eNOS and brieﬂy elevation of [Ca2+]i is thus required to facil-
itate the activation of eNOS [19,20]. Our results shown that Re
induces peak NO production (100 s) follows elevation in
[Ca2+]i at around 60 s. Previous reports on Rg1, another angio-
genic ginsenoside of the same structural category as Re, and
Dex, a speciﬁc GR agonist, showed a peak eNOS phosphory-
lation and NO production were observed at 30–60 min via
PI3K/Akt pathway [10,21]. The time-point discrepancy be-
tween Re and Rg1/Dex can be explained by the fact that reg-
ulation of eNOS activation is bimodal. Calcium-calmodulin
activation of eNOS leads to immediate NO synthesis until
the binding of the heat shock protein (hsp)-90 to the eNOS,
and then Akt phosphorylation activation of eNOS takes over
and accounts for the second phase [22]. Re was recently dem-
onstrated to be able to stimulate NO release via the PI3K/Akt
pathway in cardiac myocytes [23], we believe it would exhibit
the same actions in endothelial cells like Rg1 [10]. Calcium-cal-
modulin-dependent activation of eNOS and NO production is
a major determinant of the vascular tone [24–26], indicating
Re can potentially be used as a new modality in treating hyper-
tension. Moreover, there are more evident that NO is more
than just a vasodilator, it was also shown to play a key role
in postnatal angiogenesis, though the precise mechanisms of
how NO regulates angiogenesis is still unclear [27–30].
From the inhibitory assays, both GR antagonist RU486 and
GR siRNA signiﬁcantly reduced the Re-mediated Ca2+ inﬂux
and NO production from the endothelial cells (Fig. 5). Estro-
gen receptor (ER), the second largest population of nuclear
receptors in the endothelial after GR, was also investigated
for the possible role in the Re-induced non-genomic responses
in endothelial cells. Pretreatment with speciﬁc ER antagonist
ICI 182,780 have no inhibitory eﬀects (data not shown), indi-
cating the eﬀects of Re is GR-mediated, but not ER. Further,
we established a direct correlation between Re and the GR
using competitive ligand-binding and reporter gene assays.
We demonstrated for the ﬁrst time that Re is a functional li-
gand of the GR and the Kd and IC50 were 49.7 nM and
156.6 nM, respectively (Fig. 4A). Our previous study had re-
ported Rg1 binds to GR with a slightly stronger aﬃnity than
that of Re as demonstrated using the same competitive binding
assay [10]. The lower aﬃnity of Re, in comparison with Rg1,
might due to presence of the additional rhamnose at the C-6position that causing steric bump during Re–GR interaction,
complete understanding warrants detailed structural analysis.
GR, a member of the nuclear receptor superfamily, exists
abundantly in almost all cell types. Besides the classical tran-
scriptional activation of GR, there is accumulating evidence
showing the physiological importance of the GR-mediated
non-transcriptional ‘‘rapid’’ pathways [21,31,32]. The ability
for Re to stimulate rapid calcium inﬂux and NO production,
as well as to transactivate genes regulated by GRE, suggesting
Re is both non-transcriptional and transcriptional agonist to
GR. Thus, administration of Re could modulate a broader
spectrum of biological processes, including secretion, metabo-
lism, gene transcription and even apoptosis, via GR-mediated
calcium signaling [33–36].
Collectively, we have clearly demonstrated that the ginseno-
side-Re can act as an agonist for GR, eliciting Ca2+ inﬂux and
NO production. Re, as an angiogenic modulator, can be
exploited to be a new modality in angiotherapy to treat path-
ological conditions involving insuﬃcient angiogenesis, for
examples, chronic wounds and ischemic diseases.
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